Revlimid (lenalidomide) is a brand-name oral capsule that’s prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...
SurvivorNet on MSN
For high-risk lymphoma, adding targeted drugs tafasitamab and lenalidomide to standard treatment keeps cancer away for longer
The frontMIND study adds two immune‑based medicines (tafasitamab and lenalidomide) to standard R‑CHOP, a type of chemotherapy, which helped patients stay in remission longer, reducing the risk of the ...
Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody ...
Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial). This is an ASCO ...
Monjuvi, combined with Revlimid and Rituxan, significantly improves progression-free survival in relapsed/refractory follicular lymphoma, as shown in the inMIND trial. The trial reported a median ...
Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI), who may also be ineligible for autologous stem cell ...
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study The ideas and opinions expressed in this Data ...
Topline results from Phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-fr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results